Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe

For further information on this analysis, please visit: http://frost.ly/62g For further information on this analysis, please visit:http://frost.ly/62g "Advances in RNA stability, manufacturing, chemical modification, and targeted delivery systems have led to the commercial translation of RNA therapeutics," said Ruplekha Choudhurie, TechVision Industry Analyst at Frost & Sullivan. "RNAs are relatively easy to manufacture, cost-effective, and can act on undruggable targets...

SANTA CLARA, Calif., 22/07/2021 (informazione.news - comunicati stampa - editoria e media)

"Advances in RNA stability, manufacturing, chemical modification, and targeted delivery systems have led to the commercial translation of RNA therapeutics," said Ruplekha Choudhurie . "RNAs are relatively easy to manufacture, cost-effective, and can act on undruggable targets. As a result, academic labs and small biotech companies are accelerating RNA therapeutics research, alongside Tier 1 biopharmaceutical companies."

Choudhurie added: "RNAs have certain advantages over deoxyribonucleic acid (DNA) and small molecule drugs, such as eliminating the risk of genomic integration, being relatively cost-effective, and having rapid development and production. Hence, RNA therapeutics investment has a better chance of commercial success and enables better returns in less time for market participants. Specifically, for the development of vaccines for COVID-19 and other emerging infectious disease outbreaks, mRNA vaccines have an advantage over other types of vaccines as they can be rapidly developed and amenable to modifications to target evolving viral variants."

The advantages of RNA therapeutics over conventional small molecule drugs and other biological drugs present immense growth opportunities for market players, including:

 is the latest addition to Frost & Sullivan's research and analyses available through the Frost & Sullivan Leadership Council, which helps organizations identify a continuous flow of growth opportunities to succeed in an unpredictable future.

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Mariana Fernandez
Corporate Communications
E: Mariana.Fernandez@frost.com
http://ww2.frost.com